Last reviewed · How we verify
NCT04441775
Artificial Intelligence for Prostate Cancer Treatment Planning
trial testing AI-assisted RT modelling in Prostate Cancer in 5 participants. Completed in 4 March 2022.
30 November 2021
Quick facts
| Lead sponsor | Dartmouth-Hitchcock Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 5 |
| Start date | 22 June 2020 |
| Primary completion | 30 November 2021 |
| Estimated completion | 4 March 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- AI-assisted RT modelling
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
- Artificial Intelligence — all drugs for Artificial Intelligence →
- Radiotherapy — all drugs for Radiotherapy →
Sponsor
Dartmouth-Hitchcock Medical Center
Who can join
Adults 21 to 90, male only, with Prostate Cancer or Artificial Intelligence. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project's goal is to develop and test an application that uses Artificial Intelligence (AI) to improve consistency and quality of Radiation Treatment (RT) plans for prostate cancer. By understanding expert planner preferences in structure contouring and treatment planning, and combining this framework with planning data and outcomes amassed in NRG clinical trials, AI models may be trained to produce contours and treatment plans that are indistinguishable or even potentially deemed superior to those produced by individual experts. At the conclusion of this contract, the awardees will provide a software product which, when given the input of a description of desired anatomical target volumes and target doses along with a patient's CT scans, will generate target volumes and radiation treatment plans based upon a "gold standard" amalgamated from the input of multiple experts, thereby achieving desired doses to target volumes while meeting or exceeding the dose-volume constraints imposed by adjacent normal tissues.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
NRG Oncology Assessment of Artificial Intelligence for Automatic Treatment Planning in Radiation Therapy Clinical Trials: Present and Future.
Jia X, Rong Y, Wu Q, Cardenas CE, et al · · 2025 · cited 2× · PMID 40164355 · DOI 10.1016/j.ijrobp.2025.03.045 -
Artificial Intelligence in Oncology: A 10-Year ClinicalTrials.gov-Based Analysis Across the Cancer Control Continuum.
Verma H, Mistry S, Jayam KV, Shrestha P, et al · · 2025 · PMID 41228330 · DOI 10.3390/cancers17213537
Verify or expand the search:
- PubMed search for NCT04441775
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Dartmouth-Hitchcock Medical Center trials
Trials by the same sponsor.
- NCT07325474 — Plan and Protect: Safety Planning for Teens in Rural Emergency Departments · NA · not yet recruiting
- NCT07428629 — Piloting an Insomnia Treatment in Patients With Ulcerative Colitis · NA · not yet recruiting
- NCT06777511 — Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients · not yet recruiting
- NCT07279116 — ABY-029 Head & Neck Trial · Phase 1 · not yet recruiting
- NCT07063693 — ABY-029 Glioma Trial · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04441775 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dartmouth-Hitchcock Medical Center
- Last refreshed: 13 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04441775.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing